Retension Pharmaceuticals, Inc. Common Stock (RTSN)

• Market cap: $117M
• 1 day: 15.23%
• 5 days: 29.32%
• 1 month: 33.62%
• 3 months: 33.62%
• 6 months: 33.62%
• Year to date: 33.62%
• 1 year: 33.62%
• 5 years: 33.62%
• 10 years: 33.62%
• Sector: Healthcare
• Industry: Biotechnology

About: Retension Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (PDE-5) inhibitor designed to reduce blood pressure.